Irodalom:
1. Bjarnason I. et al: Intestinal permeability: An overview. Gastroenterology 1995; 108: 1566-1581.
2. Bjarnason I. et al: The G.U.T. of Gut. Scand J Gastroenterol 2004; 39: 807-815.
3. Bjarnason I., PETERS T.: Influence of anti-rheumatic drugs on gut permeability and on the gut associated
lymphoid tissue. Bailliere’s Clinical Rheumatology 1996; 10 (1): 165-176.
4. Beró T., Jávor T.: The effect of cytostatics on the intestinal absorption of D-xylose in patients with
malignant lymphoma. Acta Med Hung 1983; 40 (4): 247-250.
5. Beró T., Jávor T.: The effect of cyclophosphamide and vincristine on intestinal protein loss in rats. Arch
Toxicol 1985; 8: 117-121.
6. Beró T.: The effect of cyclophosphamide and vincristine on glucose absorption in rats using in vivo perfusion
experiments. Acta Med Hung 1986; 436 (4): 369-372.
7. Beró T.: A malabsorptio immunvonatkozásai. Quart Bull Hung Gastroent Soc 1985; 3: 23-32
8. Bjarnason I., Peters T.: A persistent defect in intestinal permeability in coeliac disease demonstrated by
a 51Cr-labelled EDTA absorption test. The Lancet 1983; 1: 323-325.
9. Beró A.: Gyulladásos bélbetegségek reumatológiai vonatkozásai. Magyar Reumatológia 1995; 36: 96-105.
10. Banan A. et al: Ethanol-induced barrier dysfunction and its prevention by growth factors in human
intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. Issue 1999; 291 (3): 1075-1085.
11. Söderholm J.D., PERDUE M.H.: Stress and the gastrointestinal tract II. Stress and intestinal barrier
function. Am J Physiol Gastrointest Liver Physiol 2001; 280: G7-G13.
12. Miller A.L.: The pathogenesis, clinical implications, and treatment of intestinal hyperpermeability. Alt
Med Rev 1997; 2 (5): 330-345.
